HTML ad tag preview - Powered by Ad Reform

Live Preview

Tag didn’t load? Click here and let us know!

55x16

1.78 KB

Share this result

Previews are deleted daily. Get a permanent share link sent to your inbox:

Script

Open in browser

<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <title>DIGIFab - Clinical Monitoring Opportunity</title>
  <style>
    body {
      margin: 0;
      padding: 0;
      font-family: sans-serif;
      display: flex;
      align-items: center;
      height: 90px;
    }
    .container {
      width: 720px;
      display: grid;
      grid-template-columns: 55px 1fr; /* Allocate space for logo and content */
      align-items: center;
      height: 100%;
    }
    .logo {
      width: 55px;
      grid-row: 1;
      margin: 4px 10px 0px 2px; /* Added small margins for logo */
    }
    .content {
      grid-row: 1;
      display: flex;
      flex-direction: column;
      line-height: 1; /* No line spacing between elements */
      margin: 0;
      padding: 0; /* Remove default padding */
      font-size: 11px;
    }
    .heading {
      font-weight: bold;
      margin-bottom: -1px; /* Negative margin to eliminate spacing */
      color: #014757; /* Use button color for emphasis */
    }
    .subheading {
      font-weight: bold;
      margin-bottom: -1px; /* Negative margin to eliminate spacing */
    }
    .text {
      margin-bottom: 0; /* Eliminate margin after text */
    }
    .button {
      background-color: #014757;
      color: white;
      padding: 2px 5px; /* Set padding to accommodate text and avoid overflow */
      border: none;
      border-radius: 5px;
      cursor: pointer;
      text-decoration: none;
      display: inline-block;
      margin-top: 2px; /* Reduced margin before button */
      white-space: nowrap; /* Prevent text wrapping within button */
      overflow: hidden; /* Hide overflowing text */
      text-overflow: ellipsis; /* Add ellipsis (...) if text overflows */
    }
    .scroll-box {
      width: 250px; /* Adjust width as needed */
      height: 200px; /* Adjust height as needed */
      overflow-y: scroll; /* Enable vertical scrolling */
      border: 1px solid #ccc;
      padding: 10px;
      margin-left: 10px; /* Adjust margin as needed */
    }
  </style>
</head>
<body>
  <div class="container">
    <img class="logo" src="https://serb.com/wp-content/uploads/2022/09/SERB-logo-200x57-1.svg" alt="SERB Logo">
    <div class="content">
      <p class="heading">Clinical Monitoring Opportunity!</p>
      <p class="subheading">Monitor Digoxin Levels for Patient Safety</p>
      <p class="text">This patient is on digoxin. Monitoring levels (~6 hours post-dose) is crucial for early detection of life-threatening toxicities. Act now and verify digoxin levels are within therapeutic range to optimize patient care. Click to Learn More:</p>
      <a href="https://digifab.health/en-us/digoxin-toxicity/potentially-fatal-digoxin-toxicity.html" class="button">Potentially Fatal Digoxin Toxicity | DIGIFab</a>
    </div>
    <div class="scroll-box">
      <p><strong>INDICATIONS AND USAGE</strong></p>
      <p>DIGIFab is indicated for the treatment of patients with life-threatening or potentially life-threatening digoxin toxicity or overdose, including:</p>
      <ul>
        <li>Known suicidal or accidental consumption of fatal doses of digoxin: 10 mg or more of digoxin in healthy adults, or 4 mg (or more than 0.1 mg/kg) in healthy children, or ingestion of an amount that can cause steady state serum concentrations of ≥10 ng/mL;</li>
        <li>Chronic ingestions causing steady-state serum digoxin concentrations >6 ng/mL in adults or 4 ng/mL in children;</li>
        <li>Manifestations of life-threatening toxicity of digoxin overdose such as severe ventricular arrhythmias, progressive bradycardia, and second or third degree heart block not responsive to atropine, serum potassium levels exceeding 5.5 mEq/L in adults or 6 mEq/L in children with rapidly progressive signs and symptoms of digoxin toxicity.</li>
      </ul>
      <p><strong>IMPORTANT SAFETY INFORMATION</strong></p>
      <p>Warnings and Precautions</p>
      <ul>
        <li>General</li>
        <li>Suicidal ingestion may result from more than one drug. Consider toxic effects of other drugs or poisons in cases where signs and symptoms of digitalis toxicity are not relieved by administration of DIGIFab.</li>
        <li>Rapid drop in serum potassium concentration may occur after treatment. Monitor frequently.</li>
        <li>...</li>
      </ul>
      <p><strong>Adverse Reactions</strong></p>
      <ul>
        <li>The most common adverse reactions (>7%) related to DIGIFab administration are worsening congestive heart failure (13%), hypokalemia (13%) and worsening atrial fibrillation (7%).</li>
      </ul>
      <p><a href="https://digifab.health/getmedia/f821face-fe6e-4105-8090-5b81816942f0/DigiFab-PI_P12011E_A4-Updated-June2017.pdf">Please see full Prescribing Information</a></p>
    </div>
  </div>
</body>
</html>

Landing Page

This ad does not have a landing page available

Network Timeline

Performance Summary

Requests

Domains

5KB

Transfer Size

13KB

Content Size

63.0ms

Dom Content Loaded

89.0ms

First Paint

164.0ms

Load Time

Domain Breakdown

Transfer Size (bytes)

Content Size (bytes)

Header Size (bytes)

Requests

Timings (ms)

Total Time

Content Breakdown

Transfer Size (bytes)

Content Size (bytes)

Header Size (bytes)

Requests